ILD Clinical Trials

1. Interstitial Lung Disease Registry
   The Interstitial Lung Disease Registry is a database of the clinical features of patients with interstitial lung disease that allows researchers to better define the characteristics of these diseases, their potential causes, and their natural history. The registry includes demographics, clinical metrics and survey questionnaires. [email protected].
2. Interstitial Lung Disease Blood and Tissue Repository
   The Interstitial Lung Disease Blood and Tissue Repository is a collection of serum, plasma, lung fluid, and lung tissue that is linked to the Interstitial Lung Disease Registry. These samples allow researchers to investigate biological mechanisms of disease and relate their findings to clinically important measures like symptom severity and disease progression. Contact at: [email protected].
3. MOUNTAIN Study - Defining the molecular and radiologic phenotype of progressive RA-Interstitial Lung Disease (RA-ILD)
4. TETON/RIN-PF-301- A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
5. TETON/RIN-PF-302- An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease
6. EGCG - Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect
7. ABCVILD- Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease
8. Moonscape (GB44496) -  A two-cohort, phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab compared with placebo in patients with IPF and in patients with Systemic Sclerosis Associated ILD – Enrolling for Cohort 1
9. Daewoong - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis
10. CPI-IFE-008- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study with an Open-Label Extension to Determine the Safety and Efficacy of Oral Ifetroban in Patients with IPF

1.  Telomere Study- Implementing Telomere Length Testing in Pulmonary Fibrosis
2. BEACON- A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexograst) for the treatment of idiopathic pulmonary fibrosis
3. IM027-068- A multicenter, randomized, double-blind, placebo-controlled, Phase 3 Study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with idiopathic pulmonary fibrosis (IPF)
4. IM027-1015- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (PPF)
5. AP01-007- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants with Progressive Pulmonary Fibrosis (PPF)​​​​​​

​​​

1. ORV-PF-201- A Double-Blind, Randomized, Placebo-Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis
2. Horizon Study- A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis